These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7606586)

  • 21. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
    Birawska I; Fuchs J; Szulakowska E
    Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria.
    Kuck NA; Petersen PJ; Weiss WJ; Testa RT
    J Chemother; 1989 Jun; 1(3):155-61. PubMed ID: 2552030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus.
    Henson KE; Yim J; Smith JR; Sakoulas G; Rybak MJ
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro susceptibilities of Capnocytophaga isolates to beta-lactam antibiotics and beta-lactamase inhibitors.
    Jolivet-Gougeon A; Buffet A; Dupuy C; Sixou JL; Bonnaure-Mallet M; David S; Cormier M
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3186-8. PubMed ID: 11036049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The sensitivity of clinical isolates of anaerobic species to piperacillin-tazobactam and other antimicrobial agents.
    Namavar F; Severin WP; Stobberingh E; Smeets T; MacLaren DM
    J Antimicrob Chemother; 1994 Sep; 34(3):415-9. PubMed ID: 7829416
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.
    Prabhakaran K; Harris EB; Randhawa B; Adams LB; Williams DL; Hastings RC
    Microbios; 1993; 76(309):251-61. PubMed ID: 8302203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
    Attivi D; Gibaud S
    Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior effect of tazobactam/piperacillin compared to piperacillin on beta-lactamase-producing Pseudomonas aeruginosa.
    Nishida K; Higashitani F; Hyodo A
    Chemotherapy; 1997; 43(3):171-8. PubMed ID: 9142457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Basic and clinical studies on tazobactam/piperacillin in pediatric field].
    Motohiro T; Nagai K; Yamada T; Oki S; Yamada T; Yoshinaga Y; Tsumura N; Oda K; Sakata Y; Kato H; Imai S; Morita J; Matsuo Y; Ikezawa S; Takahgashi K; Fukuda T; Yamashita Y; Aramaki M; Hayashi M; Yamakawa R; Ono-E ; Tananari Y; Tsutsumi T; Hoshuyama A; Aida K
    Jpn J Antibiot; 1998 Jun; 51(6):413-31. PubMed ID: 9755831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Pagani L; Migliavacca R; Luzzaro F; Giacobone E; Perilli M; Micheletti P; Amicosante G
    Chemotherapy; 1998; 44(6):377-84. PubMed ID: 9755296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.
    Sutherland R
    Infection; 1995; 23(4):191-200. PubMed ID: 8522374
    [No Abstract]   [Full Text] [Related]  

  • 36. Piperacillin/tazobactam in the treatment of polymicrobial infections.
    Gorbach SL
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S27-34. PubMed ID: 7962986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A three-dimensional model for in vitro study of the association of three antibiotics. Application to the activity of piperacillin, tazobactam and amikacin against five strains of enterobacteria as a function of their phenotype of beta-lactam resistance].
    Duez JM; Cordin X; Siebor E; Pechinot A; Chamard-Neuwirth C; Kazmierczak A
    Pathol Biol (Paris); 1998 Jan; 46(1):67-72. PubMed ID: 9769939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.
    Rotschafer JC; Ostergaard BE
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S15-22. PubMed ID: 7606585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Susceptibility of clinical strains of gram-positive bacteria to selected beta-lactam antibiotics].
    Sawicka-Grzelak A; Rokosz A
    Med Dosw Mikrobiol; 1998; 50(1-2):69-76. PubMed ID: 9857616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.